Skip to content
value.today

Replimune Group, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to bookPrice to book of Biotechnology: $508 M to $2.1 B, median $746 M$0 M$578 M$1.2 B$1.7 B$2.3 BMarket value $1.6 B

Your own DCF model

A full discounted-cash-flow model of Replimune Group, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times Replimune Group, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Replimune Group, Inc.Applied toValue (25th to 75th)Companies
Price to book3.1× / 4.5× / 12.9×9.9×book equity $166 M$508 M to $2.1 B69

Against its own history

Replimune Group, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

Price to book

9.9×

Now above its median of 2.0×, in the top quarter of its range; range 0.8× to 10.5× over 26 months.

0×3×5×8×11×2020202120222023202420252026Price to book 10×Median 2×

As of Oct 30, 2026

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Mar 31, 2026—$-314 M$-280 M$4 M$-285 M$-126 MSEC annual report (10-K, 20-F)
FY2024to Mar 31, 2025—$-247 M$-192 M$7 M$-199 M$-65 MSEC annual report (10-K, 20-F)
FY2023to Mar 31, 2024—$-216 M$-185 M$6 M$-191 M$-30 MSEC annual report (10-K, 20-F)
FY2022to Mar 31, 2023—$-174 M$-128 M$2 M$-130 M$-118 MSEC annual report (10-K, 20-F)
FY2021to Mar 31, 2022—$-118 M$-82 M$2 M$-85 M$-106 MSEC annual report (10-K, 20-F)
FY2020to Mar 31, 2021—$-81 M$-61 M$2 M$-64 M—SEC annual report (10-K, 20-F)